CurrentPremera BluecrossPolicy 7.01.13

Mastectomy for Gynecomastia

This policy governs when mastectomy surgery for gynecomastia (male breast tissue enlargement) is considered medically necessary or not, and what documentation and coding apply for Premera Bluecross members.

Policy Summary

PayerPremera Bluecross

PolicyMastectomy for Gynecomastia

Policy CodePolicy 7.01.13

Change TypeAnnual review — no material changes

Effective DateMay 1, 2026

Next Review DateMay 1, 2026

Key ActionObtain prior authorization and submit clinical documentation demonstrating ASPS grade, duration of symptoms, failed conservative therapy, and glandular tissue causing functional impairment.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Grade III-IVRequired gynecomastia severity

2 yearsPersistence after ruling out causes

6 monthsMedication discontinuation period

19300Principal procedure code

NoneMedicare NCD

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Non-malignant indications (Adults and adolescents)

Mastectomy surgery for non-malignant gynecomastia may be considered medically necessary when ALL of the following are met:

Non-malignant mastectomy criteria: Glandular (not fatty/adipose) breast tissue is causing a physical functional impairment.required

Document that tissue is glandular and interferes with normal physical functioning.

Non-malignant mastectomy criteria: Unilateral or bilateral Grade III or Grade IV gynecomastia is present (per American Society of Plastic Surgeons Gynecomastia Scale).Severity = Grade III or IV

Use ASPS grading scale in documentation.

Non-malignant mastectomy criteria: Persists 2 years after pathological causes (e.g., hormonal, endocrine, or liver disease) are ruled out or treated.Duration = 2 years after ruling out/ treating pathological causes

Non-malignant mastectomy criteria: Persists after 6-month discontinuation of medications, nutritional supplements, or substances that could be the underlying cause, when medically appropriate and applicable (examples: testosterone, marijuana, anabolic steroids, topical lavender oil/tea tree oil, anti-androgens, tricyclic antidepressants, cimetidine, digoxin, calcium channel blockers).6 months after discontinuation when applicable

Non-malignant mastectomy criteria: Pain and discomfort from the distention and tightness due to the hypertrophied breast(s) has not responded to medical management (e.g., analgesics or anti-inflammatories).failed medical management

Non-malignant mastectomy criteria: If any element is not met, mastectomy is considered not medically necessary for non-malignant indications.

Malignant (cancer) indications

Mastectomy surgery for malignant indications:

Malignant indication: Mastectomy is considered medically necessary for diagnosed malignancy (cancer) of the breast(s) regardless of age.single condition

No prior conservative therapy required when malignancy is present.

Medically necessary criteria for non-malignant gynecomastia

Covered when ALL of the following are met (as reflected from professional society guidance and policy statements):

ASPS grade and duration: For adults: unilateral or bilateral Grade III or IV gynecomastia persisting more than 3–4 months after pathological causes are ruled out and continuing after 3–4 months of unsuccessful medical treatment. For adolescents: unilateral or bilateral Grade II or III persisting more than 1 year after pathological causes are ruled out (or 6 months if Grade IV) and continuing after 6 months of unsuccessful medical treatment.time and grade thresholds per ASPS

Based on ASPS guidance; surgical treatment may be appropriate when medical therapy fails.

Symptom-driven indication: Surgery may be appropriate when distention and tightness cause pain and discomfort or when a functional impairment is present.symptoms causing pain/functional impairment

ASPS supports symptom-based indication; align with documentation of functional impairment.

Mastectomy for gynecomastia is considered cosmetic (not covered) when it is performed solely to preserve or improve an individual's appearance, self‑esteem, or emotional/psychological well‑being and there is no physical functional impairment. The policy explicitly states that procedures done only to improve appearance in the absence of functional limitation are cosmetic and excluded from coverage.

Services that are primarily intended to improve appearance are defined as cosmetic and are not eligible for coverage. The policy reiterates that if gynecomastia treatment is requested in the absence of a documented physical functional impairment (see policy definition of Physical Functional Impairment), the procedure is considered cosmetic and excluded from coverage; determinations should be interpreted in the context of the member's specific benefit language.

Mastectomy for gynecomastia is considered not medically necessary when the required criteria for non‑malignant indications are not all met. Examples include when the tissue is not glandular (i.e., fatty only), insufficient severity (less than Grade III), insufficient duration after pathological causes are ruled out or treated (policy threshold: persists 2 years as specified), failure to discontinue causative medications/substances for the specified period when applicable (policy threshold: persists after 6 months discontinuation), or lack of failed conservative/medical management for pain/discomfort.

Procedures performed solely for cosmetic purposes — that is, those intended only to improve appearance, self‑esteem, or psychological well‑being — are explicitly identified as not medically necessary under this policy when there is no documented physical functional impairment.

Coding and Severity Indicators

Covered CPT CodesCPTCovered

19300	Mastectomy for gynecomastia
15877	Suction assisted lipectomy; trunk

Severity grade — ASPS gynecomastia grade required (Grade III–IV)

Required ASPS severityUnilateral or bilateral Grade III or Grade IV gynecomastia (ASPS Gynecomastia Scale)

Clinical documentationSeverity must be described as moderate to marked (Grade III–IV) in the medical record

Use for surgical eligibilityGrade III–IV required to meet non-malignant surgery criteria; absence of this severity makes surgery not medically necessary

Duration after ruling out pathological causes — symptom persistence requirement (2 years)

Required persistence after ruling out pathological causesGynecomastia must persist for 2 years after pathological causes are ruled out or treated

Documentation expectationRecords should state that gynecomastia persisted for 2 years after no other possible medical causes were found

Implication for coverageIf 2-year persistence criterion is not met, mastectomy is considered not medically necessary for non-malignant indications

Medication/substance discontinuation — required period after cessation (6 months) when applicable

Required discontinuation periodGynecomastia must persist after a 6-month discontinuation of causative medications, supplements, or substances when medically appropriate and applicable

Examples of causative agentsIncludes testosterone, marijuana, anabolic steroids, topical lavender/tea tree oil, anti-androgens, tricyclic antidepressants, cimetidine, digoxin, calcium channel blockers

Documentation expectationMedical records should document the 6-month discontinuation and persistence after cessation when applicable

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is recommended when coverage depends on documentation that the member meets medical necessity criteria. Providers should obtain prior authorization for procedures such as CPT 19300 and CPT 15877 when the indication and documentation will determine coverage. The prior authorization review will use this policy to determine medical necessity.

Affected codes: CPT 19300 (Mastectomy for gynecomastia), CPT 15877 (Suction assisted lipectomy; trunk)
Obtain PA when coverage depends on documented criteria in this policy

Denial Risk

Denial Triggers / Coverage Exclusions

Requests will be denied if required clinical criteria, duration of symptoms, prior conservative or medical therapy, or adequate documentation are not met or not provided with the request.

Denial triggers include: lack of documented glandular (vs fatty) tissue, ASPS grade not III or IV as required, symptoms present for less than required duration, absence of documentation ruling out or treating pathological causes, failure to document attempted medication/substance discontinuation when applicable, and lack of attempted medical management for pain/discomfort
Procedures performed solely to improve appearance, self-esteem, or psychological well‑being without functional impairment are cosmetic and not covered

Documentation Required

Required Documentation

Medical records submitted for review must document that the medical necessity criteria are met. Include all required clinical findings, history, and treatment attempts.

Documentation must show the tissue to be removed is glandular breast tissue and that it interferes with normal physical functioning
Document ASPS severity grade (grade III or IV) and whether gynecomastia is unilateral or bilateral
Document duration: persists 2 years after pathological causes are ruled out or treated (or other applicable durations per guidelines) and persists after a 6‑month discontinuation of causative medications/supplements/substances when medically appropriate
Document that pain and discomfort related to the enlargement have not responded to medical management (e.g., analgesics, anti‑inflammatories)

Documentation Required

Required Clinical Documentation (Detailed)

Clinical documentation should specifically reflect the ASPS gynecomastia grade, duration of symptoms, details of prior medical management (including medications stopped and timing), evaluation and treatment of pathological causes, and current physical findings.

ASPS grade (III or IV) and description of physical exam findings (skin redundancy, feminization, distinct edges, etc.)
Dates and outcomes of evaluation/treatment for pathological causes (hormonal, endocrine, liver disease)
Evidence of a 6-month trial off potential causative medications/supplements/substances when applicable
Description of prior conservative therapies and response (weight loss attempts, cessation of causative agents, analgesics/anti‑inflammatories)

Step Therapy

Conservative Therapy Prerequisites

Conservative therapies addressing underlying causes should be attempted before surgery unless not possible. Treatment options to try include addressing hormonal or endocrine disorders, weight loss, and cessation of causative drugs or supplements when medically appropriate.

Treat underlying hormonal/endocrine disorders or liver disease where identified
Cessation of causative medications, nutritional supplements, or substances when medically appropriate (e.g., testosterone, marijuana, anabolic steroids, topical lavender/tea tree oils, anti‑androgens, tricyclic antidepressants, cimetidine, digoxin, calcium channel blockers)
Weight loss and lifestyle interventions when applicable
Analgesics or anti‑inflammatories for pain management prior to considering surgery

Step Therapy

Medical Therapy Requirement

Medical therapy should be attempted for an appropriate duration before surgical intervention when applicable. Duration expectations vary by age and severity; document attempts and response.

Adolescents: follow ASPS guidance—medical therapy attempted for up to 6 months where applicable (longer if guidance indicates)
Adults: document a trial of medical management (per ASPS recommendations, often several months) and lack of response prior to surgery
If medical therapy is contraindicated or not applicable, document rationale

Definitions and Clinical Concepts

Physical Functional Impairment — definition and examples of functional impairment

DefinitionA limitation from baseline physical functioning caused by the breast tissue (e.g., problems with ambulation, mobilization, respiration, eating/swallowing, skin integrity, distortion of nearby body parts, or obstruction of an orifice)

Cause types includedMay be due to structure, congenital deformity, pain, or other causes; must be attributable to glandular breast tissue rather than psychosocial effects

ExclusionsExcludes social, emotional, or psychological impairments as the basis for functional impairment

Cosmetic — definition of cosmetic services

DefinitionServices primarily intended to preserve or improve appearance; cosmetic surgery reshapes normal body structures to improve appearance or self-esteem

Coverage implicationProcedures performed solely to improve appearance, self-esteem, or psychological well‑being in the absence of a functional impairment are considered cosmetic and not covered

Distinction from reconstructiveReconstructive surgery is performed to improve function of abnormal structures caused by congenital defects, trauma, infection, tumors, or disease

True gynecomastia vs pseudo-gynecomastia — distinction between glandular vs fatty enlargement

True gynecomastiaGlandular proliferation with a palpable, rubbery or firm mass concentric to the nipple — requires glandular tissue for surgical indication

Pseudo-gynecomastia (lipomastia)Fat deposition/adipose tissue without glandular proliferation — considered fatty enlargement, not true gynecomastia

Coverage implicationTissue must be glandular (not fatty) and cause functional impairment for mastectomy to be medically necessary

ASPS Gynecomastia Grade I–IV — grading scale summary (I–IV) used in severity assessment

Grade ISmall breast enlargement with localized button of tissue concentrated around the areola

Grade IIModerate enlargement exceeding areola boundaries with indistinct edges from the chest

Grade IIIModerate enlargement exceeding areola boundaries with distinct edges and skin redundancy

Grade IVMarked enlargement with skin redundancy and feminization of the breast

OpenPayer

Mastectomy for Gynecomastia

Coverage Criteria for Mastectomy for Gynecomastia

Coding and Severity Indicators

Provider Actions, Prior Authorization, and Documentation

Definitions and Clinical Concepts

Background